Kappa and Mu Opioid Agonists and Antagonists
Kappa opioid agonists for pain, itch, and anxiety without side effects (sedation, dysphoria, diuresis. In vivo testing of target. DMPK studies ongoing. (S-T00362) and a new class (PROV filed 10-2023) with EC50, EMAX in 2-3 assays, microsomal stability stu Novel selective MOR agonists, MOR antagonists, KOR agonists, and KOR antagonists based on natural product GB18. […]
New Steroidal Alkaloid-Based Therapeutics for Chronic Pain
Osteoarthritis steroidal compounds Nine-step synthesis allowed for flexible synthesis of analogues In vivo evaluation of compounds
Small Molecule Modulators of Orphan Receptor Complex for Powerful Anti-Opioid Activity and Methods Related to Opioids Therapeutics
Augmentation of opioid-induced analgesia with substantially reduced dependency Lack of withdrawal upon cessation of chronic morphine administration
Nanobody Targeting an Orphan Receptor for Anti-Depressive Therapeutic Benefits
Targeting major depressive disorder (MDD) Novel class of anti-depressants Powerful anti-depressant effect in in vivo studies Non-invasive delivery route
Novel Morphine Framework Derivatives
Analogues of morphine that are µ-receptor partial agonists Retain analgesic effect without side-effects seen with morphine
Metabolically Stable Sigma Receptor Ligands
Sigma receptors are highly expressed in CNS and targets for psychostimulant Antagonist sigma receptor compounds with long-lasting analgesic effect Metabolic stability, binding affinity, in vivo studies
G-Protein Biased Opioid Receptor Agonists
Reduced beta-arrestin recruitment G-protein biased analgesics have fewer side effects such as respiratory depression and addiction found in opioids such as fentanyl and morphine
Novel Compounds To Treat Neuropathic and Inflammatory Pain
Novel silent agonists of alpha9 nicotinic acetylcholine receptors (nAChR) Effective as non-opioid analgesics
Identification of a Shorter and More Effective Form of Surface Layer Protein a (SlpA) of Lactobacillus acidophilus Against Inflammatory Disorders
SlpA of L. acidophilus has a potent anti-inflammatory effect and is being developed to treat IBD, IBS, UC and Crohn’s disease Fragments of SlpA have greater anti-inflammatory activity than the full-length protein POC demonstrated in mouse model of colitis